Summary & Overview
HCPCS Level II A9583: Injection, Gadofosveset Trisodium, 1 ml
HCPCS Level II code A9583 designates a 1 ml injection of gadofosveset trisodium, a gadolinium-based contrast agent used to enhance magnetic resonance imaging studies, particularly vascular and tissue characterization. The code is clinically significant for facilities and imaging providers because it specifies the administered contrast product and unit volume, which affects inventory tracking, billing line-itemization, and reimbursement processing at the national level.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payment and coverage considerations across major commercial and federal payers, context on typical sites of service where this injectable agent is used, and operational implications for imaging departments. The publication outlines benchmarking elements relevant to charge capture and claim submission, notes any recent policy updates affecting contrast agent coding and coverage where available, and explains clinical circumstances that commonly prompt use of the agent.
This resource targets coding professionals, revenue cycle staff, and radiology administrators seeking a national-level reference for coding, billing, and administrative handling of HCPCS Level II code A9583. Data not available in the input will be identified explicitly in the appropriate sections.
Billing Code Overview
HCPCS Level II code A9583 describes an injection of gadofosveset trisodium, 1 ml. This code indicates administration of a specific gadolinium-based intravenous contrast agent used for enhanced magnetic resonance imaging (MRI) vascular and tissue imaging.
-
Service type: Injectable contrast agent for diagnostic imaging
-
Typical site of service: Hospital outpatient departments, imaging centers, and diagnostic radiology suites
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred for contrast-enhanced magnetic resonance angiography (MRA) or MR venography to evaluate suspected vascular pathology such as peripheral arterial disease, carotid artery stenosis, aortic aneurysm, or pre-procedural vascular mapping. The patient often presents with symptoms like limb claudication, neurologic transient ischemic attacks, pulsatile abdominal mass, or graft assessment needs. Prior to the study, the radiology team confirms indications, reviews allergy and renal function (eGFR), and obtains informed consent specific to gadolinium-based contrast. On the day of service, an intravenous access is established, standard MRI safety screening is completed, and vital signs are documented. The radiology technologist prepares the dose of A9583 (gadofosveset trisodium) per manufacturer dosing guidelines; the radiologist or qualified supervising physician oversees administration. The contrast is injected by a registered nurse or technologist under protocol during the MR sequence; image acquisition occurs immediately following injection. Post-procedure monitoring is brief, focused on immediate hypersensitivity or renal complications. Documentation in the medical record includes the administered volume of A9583, lot number, injection site, performing clinician, relevant ICD-10 diagnosis code(s), and any immediate adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |